


### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) An 8-aza-bicyclo[3.2.1]octane derivative of the Formula I:



or any of its isomers or any mixture of its isomers,

or a pharmaceutically acceptable salt thereof,

wherein

R<sup>a</sup> represents hydrogen;

X represents -O-;

R<sup>b</sup> represents an aryl or a heteroaryl group selected from monosubstituted phenyl, naphthyl, pyridyl, quinolinyl, isoquinolinyl or quinazolinyl,

which aryl or heteroaryl group is substituted with one or two substituents independently a substituent selected from the group consisting of [ : ]

halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, and alkoxy; or

with the proviso that the compound is not

3-(3-trifluoromethyl phenoxy) 8-aza-bicyclo[3.2.1]octane,

2-(4-trifluoromethyl phenoxy) 8-aza-bicyclo[3.2.1]octane,

3-(2-bromo phenoxy) 8-aza-bicyclo[3.2.1]octane,

3-(4-chloro phenoxy) 8-aza-bicyclo[3.2.1]octane, or

3-(4-fluoro phenoxy) 8-aza-bicyclo[3.2.1]octane

R<sup>b</sup> represents an aryl group selected from disubstituted phenyl which group is substituted with substituents independently selected from the group consisting of halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, and alkoxy; or

R<sup>b</sup> represents a heteroaryl group selected from naphthyl, pyridyl, quinolinyl, isoquinolinyl or quinazolinyl, which heteroaryl group is substituted with one or two substituents independently selected from the group consisting of halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, and alkoxy.

2. – 8. (Cancelled).

9. (Previously Presented) The chemical compound of claim 1, wherein  
R<sup>b</sup> represents a pyridyl group,  
which pyridyl group is substituted with one or two substituents independently selected  
from the group consisting of:  
halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy and alkoxy.

10. (Currently Amended) The chemical compound of claim 1, which is  
*exo*-3-(2,3-Dichlorophenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(3,4-Dichlorophenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(3-Chloro-4-fluorophenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
~~*exo*-3-(3-Chloro-phenoxy)-8-H-8-azabicyclo[3.2.1]octane;~~  
*exo*-3-(4-Chloro-3-fluorophenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
~~*exo*-3-(4-Chloro-phenoxy)-8-H-8-azabicyclo[3.2.1]octane;~~  
*exo*-3-(2-Chloro-3-trifluoromethyl-phenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*endo*-3-(3,4-Dichlorophenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(4-Chloro-3-trifluoromethylphenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(3-Chloro-4-cyanophenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(4-Chloro-3-methylphenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(4-Chloronaphthalen-1-yloxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(5-Chloro-pyridin-2-yl)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(4-Methoxyphenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(6-Bromo-naphthalen-2-yloxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(4-Bromo-3-chloro-phenoxy)-8-H-8-azabicyclo[3.2.1]octane;

*exo*-3-(4-Cyanophenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(4-Methylphenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(6-Chloropyridin-2-yloxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(5-Bromopyridin-2-yloxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(6-Bromopyridin-2-yloxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(3-Trifluoromethoxyphenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(4-Trifluoromethoxyphenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(6-Methoxypyridin-2-yloxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(5-Trifluoromethylpyridin-2-yloxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(6-Ethoxypyridin-2-yloxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(4-Fluoro-3-trifluoromethylphenoxy)-8-H-8-azabicyclo[3.2.1]octane;

or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.

11. (Original) A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

12.-15.(Cancelled).

16. (New) The chemical compound of claim 1, comprising:  
*exo*-3-(3-Chloro-phenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
*exo*-3-(4-Chloro-phenoxy)-8-H-8-azabicyclo[3.2.1]octane;  
or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.